GUARD-IT: Generating Unique Single Domain Antibody-based Chimeric Antigen Receptors for Directed ImmunoTherapy
GUARD-IT develops an innovative and versatile pipeline for single domain antibody (sdAb)-based CAR-T cell discovery and validation for academic point-of-care CAR-T cell therapy
A challenge in the development of effective CAR-T therapy is the instability of current CAR binding domains, which can limit persistence of CAR-T cells. Persistence is essential for the effectiveness of treatment. In this project, the UMCG is collaborating with Cortalix, a Groningen start-up specialized in single domain antibodies (sdAbs), to identify new stable binders for CAR-T therapy. SdAbs are small, stable and excellent candidates as binders for CAR-T therapy. The project goal is to develop innovative Point-of-Care (PoC) CAR-T cell products for new indications utilizing sdAbs. Hereto, prototype sdAb-CAR constructs will be developed using a new CAR-tailored library and will be validated preclinically at the UMCG, with the aim of selection for near-future clinical production in our academic PoC CAR-T program.
GUARD-IT’s mission is to make PoC therapy of innovative CAR-T prototypes a reality for cancer patients in the Netherlands. Due to long lead times and prohibitive costing of current commercial CAR-Ts, the implementation of PoC CAR-T is expected to strongly contribute to reducing mortality, as sick patients are more rapidly treated, more terminal patients will become eligible for treatment and more indications can be reimbursed. With a clear implementation path through the UMCG PoC CAR-T program, this project is expected to, in the near-future, decrease avoidable mortality.
The GUARD-IT innovations for PoC CAR-T treatment of additional indications and possible future implementation will strongly contribute to sustainable patient care. For instance, the current CD19 PoC CAR-T product costs are estimated at ~€100k/patient, whereas costs for analogous commercial CAR-Ts cost are >€350k/patient. Thus, nationwide implementation in the current indication will save ~€60 million per year. By expanding the indication area for PoC CAR-T therapy, including into orphan indications not interesting for commercial parties, treatment opportunities for new indications can be realistically provided. This project thus has a compelling economic perspective for both UMCG and Cortalix.
Andere projecten
In elk PPS-project werken kennisinstellingen, bedrijven en zorgpartijen samen aan een concrete gezondheidsvraag. Bekijk het volledige projectoverzicht.
Bekijk de programma’s
Binnen onze programma’s werken bedrijven, kennisinstellingen en regionale partners samen aan innovaties die bijdragen aan betere gezondheid en zorg.
Bekijk de partnerschappen
Strategische publiek-private partnerschappen (PPP's) zijn meerjarige samenwerkingen tussen bedrijven, kennisinstellingen en andere partijen.
Hoe kunnen we je helpen?
Heb je een vraag of wil je meer weten over Health Holland? We brengen je graag in contact met de juiste mensen, kennis en mogelijkheden om gezondheidsinnovatie te versnellen.
We hebben uw bericht ontvangen
We nemen binnen 3 tot 4 werkdagen contact met je op. Is je vraag dringend? Neem dan gerust direct contact met ons op. Hieronder zie je de contactoptie die het beste past bij je onderwerp.
Opnieuw beginnen
Er ging iets mis bij het versturen van het formulier. Probeer het opnieuw.